Measles virus vaccine live
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Measles virus vaccine live
- Clostridium butyricum (live) Tablets(Meiya)
- clostridium butyricum live tablets meiya
- crs 207 live attenuated listeria monocytogenes expressing human mesothelin
- dengue tetravalent vaccine live
- japanese encephalitis vaccine live
- live
- Live
- Live (MV)
- live attenuated zoster vaccine
- live mv
- live-attenuated zoster vaccine
- measles k
- measles live attenuated
- measles mumps and rubella combined vaccine live
- measles mumps rubella vaccine live
- measles vaccine
- Measles vaccine
- Measles vaccine (live)
- measles vaccine (MV)
- Measles Vaccine (MV)
- measles vaccine live
- Measles vaccine live
- measles vaccine mv
- measles virus live antigen
- Measles virus live antigen
And 15 more, listed on the interactive page.
- ATC classification codes
- J07BD01
Sources for recorded values
- ChEMBL ID
- CHEMBL2109211
- RxNorm IDs (RxCUI)
- 804179
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-
- Condition
- Meningococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004249
- Subject identifier
- D008589
- Condition
- Measles
- Highest recorded phase
- 2
- Condition identifier
- EFO:1002025
- Subject identifier
- D008457
- NCT00109278
- NCT03630705
- NCT03691610
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (66)
- A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
- A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group
- A Second Dose of Measles Vaccine (MV) in the Second Year of Life
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
- Additional Measles Vaccine at 4 Months of Age
- Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
- Barriers and Facilitators to MMR Vaccination Among Healthcare Workers
- Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live
- Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months
- Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)
- CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
- Early Two-dose Measles Vaccination Trial
- Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts
- Immune Reconstitution to Measles Virus of HIV Infected Children in Zambia
- Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination
- Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)
In development for (2)
- Measles Phase 2
- Meningococcal infection Phase 3